R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma
- 18 July 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (3) , 252-262
Abstract
Patients with primary CNS lymphoma (PCNSL) are treated with high-dose-methotrexate-based chemotherapy, which requires hospitalization and extensive expertise to manage related toxicity. The use of R-CHOP could overcome these difficulties, but blood-brain barrier (BBB) penetration of related drugs is poor. Tumor Necrosis Factor-a coupled with NGR (NGR-hTNF), a peptide targeting CD13+ vessels, induces endothelial permeabilization and improves tumor access of cytostatics. We tested the hypothesis that NGR-hTNF can break the BBB, thereby improving penetration and activity of R-CHOP in patients with relapsed/refractory PCNSL (NCT03536039). Patients received six R-CHOP21 courses, alone at the first course and preceded by NGR-hTNF (0.8 μg/m²) afterwards. This trial included two phases: an "explorative phase" addressing the effect of NGR-hTNF on drugs pharmacokinetics and on vessel permeability, assessed by DCE-MRI and 99mTc-DTPA-SPECT, and the expression of CD13 on tumor tissue; and an "expansion phase" with ORR as primary endpoint, where the two-stage Simon Minimax design was used. At the first stage, if {greater than or equal to}4 responses were observed among 12 patients, the study accrual would have continued (sample size: 28). Herein, we report results of the explorative phase and the first-stage analysis (n=12). CD13 was expressed in tumor vessels of all cases. NGR-hTNF selectively increased vascular permeability in tumoral/peritumoral areas, without interfering with drug plasma/CSF concentrations. NGR-hTNF/R-CHOP combination was well tolerated: there were only two SAEs and grade-4 toxicity was almost exclusively hematological, which were resolved without dose reductions or interruptions. NGR-hTNF/R-CHOP was active, with nine confirmed responses (75%; 95%CI=51-99%), eight of which were complete. In conclusion, NGR-hTNF/R-CHOP was safe in these heavily-pretreated patients. NGR-hTNF enhanced vascular permeability specifically in tumoral/peritumoral areas, which resulted in fast and sustained responses. Key Points TNF-α coupled with NGR peptide targets CD13+ tumor vessels and increases vascular permeability selectively in tumor/peritumoral areas of PCNSL. R-CHOP preceded by low-dose NGR-hTNF was not associated with unexpected toxicity, and resulted in tumor regression in 9 of 12 PCNSL patients.Keywords
This publication has 33 references indexed in Scilit:
- Selective Permeabilization of the Blood–Brain Barrier at Sites of MetastasisJNCI: Journal of the National Cancer Institute, 2013
- Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF ExampleBioDrugs, 2013
- Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of ImmunotherapyThe Journal of Immunology, 2012
- Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic TissuesJournal of Histochemistry & Cytochemistry, 2011
- Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)Clinical Cancer Research, 2010
- Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursBritish Journal of Cancer, 2009
- Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2007
- Temozolomide as salvage treatment in primary brain lymphomasBritish Journal of Cancer, 2007
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaJournal of Clinical Oncology, 2005
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003